Eastern Cooperative Group trial of interferon gamma in metastatic melanoma: An innovative study design

Clinical Cancer Research

Volumn 2, Issue 1, 1996, Pages 29-36

  Schiller, Joan H ^a   Pugh, Marian ^b   Kirkwood, John M ^c   Karp, Daniel ^d   Larson, Marilyn ^a   Borden, Ernest ^e  

^a UNIVERSITY OF WISCONSIN   (United States)

^b EMMES CORPORATION   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

^d TUFTS UNIVERSITY   (United States)

^e UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HLA-DR ANTIGENS; HUMANS; INTERFERON TYPE II; MALE; MELANOMA; MIDDLE AGED;

EID: 0030070734     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Kirkwood, J. Studies of interferons in the therapy of melanoma. Semin. Oncol. 18: 83-90, 1991.
2. Borden, E., and Sondel, P. Lymphokines and cytokines as cancer treatment: immunotherapy realized Cancer (Phila.), 65: 800-814, 1990.
3. Schiller, J. H., Willson, S. K., Bittner, G., Wolberg, W. H., Hawkins, M. J., and Borden, E. C. Antiproliferative effects of interferons on human melanoma cells in the human tumor colony-forming assay. J. Interferon Res., 6: 615-625, 1986.
4. Kleinerman, E., Kurzrock, R., Wyatt, D , Quesada, J., Gutterman, J., and Fidler, I. Activation or suppression of the tumoricidal properties of monocytes from cancer patients following treatment with human recombinant γ-interferon. Cancer Res., 46: 5401-5405, 1986.
5. Nathan, C., Murray, H., Wiebe, M., and Rubin, B. Identification of interferon-γ as the lymphokine which activates human macrophage oxidative metabolism and antimicrobial activity. J. Exp. Med., 158: 670-689, 1983
6. Basham, T. Y., and Merigan, T. C. Recombinant interferon-γ increases HLA-DR synthesis and expression. J. Immunol., 130: 1492-1494, 1983.
7. Kirkwood, J., Emstoff, M , Trautman, T., Hebert G., Nishida, Y., Davis, C., Balzer, J., Reich, S., Schindler, J., and Rudnick, S. In vivo biological response to recombinant interferon-γ during phase I dose-response in patients with metastatic melanoma. J. Clin. Oncol. 8: 1070-1082, 1990.
8. Maluish, A., Urba, W., Longo, D., Overton, W., Coggin, D., Crisp, E., Williams, R., Sherwin, S., Gordon, K., and Steis, R. The determination of an immunologically active dose of interferon-γ in patients with melanoma. J. Clin. Oncol. 6: 434-445, 1988.
9. Talmadge, J., Tribble, H., Pennington, R., Phillips, H., and Wiltrout, R. Immunomodulatory and immunotherapeutic properties of recombinani γ-interferon and recombinant tumor necrosis factor in mice. Cancer Res., 47: 2563-2570, 1987.
10. Vadhan-Raj, S., Nathan, C. F., Sherwin, S. A., Oertgen, H. F., and Krown, S. E. Phase I trial of recombinant interferon gamma by 1-hour i.v. infusion. Cancer Treat Rep., 70: 609-614, 1986.
11. Amato, D., and Andersen, J Design considerations in phase II testing of biologic response modifiers. Paper presented at the Annual Meeting of the Eastern North American Region of the Biometric Society, Boston, 1988, March 27-30.
12. Hastie, T. J., and Tibshirani, R. J. Generalized Additive Models. New York: Chapman & Hall, 1990.
13. Real, F., Oettgen, H., and Krown, S. Kaposi's sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J. Clin. Oncol. 4: 544-551, 1986.
14. Bunn, P., Foon, K., Ihde, D., Longo, D., Eddy, J., Wrinkler, C., Veach, S., Zeffren, J., Sherwin, S., and Oldham, R. Recombinant leukocyte a-interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann. Intern. Med. 101: 484-487, 1984.
15. Kirkwood, J., Harris, J., Vera, R., Sandler, S., Fischer, D., Khandekar, J., Ernstoff, M., Gordon, L., Lutes, R., Bonomi, P., Lytton, B , Cobleigh, M., and Taylor, S. A randomized study of low and high doses of leukocyte α-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial. Cancer Res., 45: 863-871, 1985.
16. Cheson, B. D., and Martin, A. Clinical trials in hairy cell leukemia. Ann. Intern. Med., 106: 871-878, 1987.
17. Creagan, E., Ahmann, D., Green, S., Long, H., Rubin, J., Schutt, A., and Dziewanowski, Z. Phase II study of recombinant leukocyte α-interferon (rIFN-alphaA) in disseminated malignant melanoma. Cancer (Phila.), 54: 2844-2849, 1984.
18. Creagan, E., Ahmann, D., Green, S., Long, H., Frytak, S., O'Fallon, J., and Itri, L. Phase II of low-dose recombinant leukocyte α-interferon in disseminated malignant melanoma. J. Clin. Oncol., 2: 1002-1005, 1984.
19. Thompson, J., Cox, W., Lindgren, C., Collins, C., Neraas, K., Bonnem, E., and Fefer, A. Subcutaneous recombinant γ-interferon in cancer patients toxicity, pharmacokinetics, and immunomodulatory effects. Cancer Immunol. Immunother. 25: 47-53, 1987.
20. Kopp, W. C., Smith, J. W., Ewel, C. H., Alvord, W. G., Main, C., Guyre, P. M., Steis, R. G., Longo, D. L., and Urba, W. J. Immunomodulatory effects of interferon-γ in patients with metastatic malignant melanoma. J. Immunother., 13: 181-190, 1993.
21. Ernstoff, M., Trautman, T., Davis, C., Reich, S., Witman, P., Balser, J., Rudnick, S., and Kirkwood, J. A randomized Phase I/II study of continuous versus intermittent intravenous interferon-γ in patients with metastatic melanoma. J. Clin. Oncol. 5: 1804-1810, 1987.
22. Creagan, E., Ahmann, D., Long, H., Frytak, S., Sherwin, S., and Chang, M. Phase II study of recombinant interferon-γ in patients with disseminated malignant melanoma. Cancer Treat. Rep. 71: 843-844, 1987.
23. Crawford, J., Ringenberg, S., Propert, K., Glenn, L., Modeas, C., Christensen, V., Jaffe, H , and Green. M. A dose response study of the biological activity of imerferon-gamma (IFN-G) in patients with advanced nonsmall cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol. Annu. Meet., 8: 867, 1989.
24. Kirkwood, J., Bryant, J., Schiller, J , Emstoff, M., Vlock, D., Borden, E., Herberman, R., Blum, R., and Whiteside, T. Determination of phenotypic and functional correlates of interferon gamma (IFN-γ) therapy of metastatic melanoma in a multi-institutional phase IB trial (ECOG 4987/4687). Proc. Am. Soc. Clin. Oncol. Annu. Meet. 10: 218, 1991.